Mulakan
ReutersReuters

Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner

RefinitivBacaan kurang dari 1 minit
KZIA

Kazia Therapeutics Ltd KZIA:

  • KAZIA THERAPEUTICS TO REQUEST FDA TYPE C MEETING TO DISCUSS OVERALL SURVIVAL DATA IN GBM AND POTENTIAL NDA FILING IN ALIGNMENT WITH FDA INITIATIVE PROJECT FRONTRUNNER

  • KAZIA THERAPEUTICS LTD - SEEKS FDA FEEDBACK ON REGULATORY PATHWAY UNDER PROJECT FRONTRUNNER FOR PAXALISIB

OceaniaReutersSaham ASSaham Australia
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini

Lebih berita dari Reuters